|
Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis
|
4-25-2013
|
|
Radius Health to Present at BIO Business Forum(R)
|
4-18-2013
|
|
Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug
|
3-12-2013
|
|
Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston
|
2-26-2013
|
|
Radius Health to Present at BIO CEO & Investor in New York
|
2-8-2013
|
|
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection
|
1-7-2013
|
|
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis
|
1-3-2013
|
|
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis
|
12-20-2012
|
|
Radius Health Withdraws Registration Statement
|
11-15-2012
|
|
Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting
|
10-12-2012
|
|
Radius Initiates Phase 2 Study of BA058-Transdermal for the Treatment of Postmenopausal Osteoporosis
|
9-27-2012
|
|
Radius Health Announces Upcoming Scientific Presentations at ENDO 2012, the Endocrine Society's 94th Annual Meeting
|
6-22-2012
|
|
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer
|
4-20-2012
|
|
Radius Health, Inc. Files Registration Statement for Proposed Public Offering
|
2-7-2012
|
|
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis
|
12-21-2011
|
|
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing
|
12-16-2011
|
|
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy
|
12-5-2011
|
|
Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
|
11-23-2011
|
|
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study
|
5-24-2011
|
|
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis
|
5-24-2011
|
|
Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes
|
6-19-2010
|
|
Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
|
8-5-2009
|
|
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
|
3-24-2009
|
|
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
|
11-20-2008
|
|
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
|
6-9-2008
|
|
Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis
|
4-2-2008
|
|
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes
|
1-30-2008
|